Stryker Co. (NYSE:SYK – Get Rating) Director Srikant M. Datar sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $286.00, for a total transaction of $286,000.00. Following the completion of the transaction, the director now directly owns 5,967 shares of the company’s stock, valued at approximately $1,706,562. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Stryker Trading Up 0.0 %
Shares of SYK opened at $285.37 on Friday. Stryker Co. has a 1-year low of $188.84 and a 1-year high of $306.56. The firm has a market capitalization of $108.33 billion, a price-to-earnings ratio of 41.54, a PEG ratio of 2.98 and a beta of 0.94. The firm’s 50-day moving average price is $286.58 and its 200-day moving average price is $261.52. The company has a current ratio of 1.73, a quick ratio of 0.99 and a debt-to-equity ratio of 0.70.
Stryker (NYSE:SYK – Get Rating) last posted its earnings results on Monday, May 1st. The medical technology company reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $2.00 by $0.14. The firm had revenue of $4.80 billion for the quarter, compared to the consensus estimate of $4.56 billion. Stryker had a return on equity of 22.17% and a net margin of 13.86%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.97 EPS. Sell-side analysts anticipate that Stryker Co. will post 10.16 EPS for the current year.
Stryker Dividend Announcement
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on SYK shares. Piper Sandler increased their target price on Stryker from $280.00 to $310.00 in a research note on Tuesday, May 2nd. Morgan Stanley raised their price objective on Stryker from $260.00 to $280.00 and gave the company an “equal weight” rating in a report on Wednesday, February 1st. Argus upped their target price on Stryker from $270.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, February 21st. 92 Resources reiterated a “maintains” rating on shares of Stryker in a research report on Tuesday, May 2nd. Finally, Stifel Nicolaus boosted their price objective on shares of Stryker from $280.00 to $330.00 in a report on Tuesday, May 2nd. Eight investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $300.86.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Norges Bank bought a new stake in shares of Stryker in the 4th quarter worth approximately $776,333,000. Moneta Group Investment Advisors LLC boosted its holdings in Stryker by 109,726.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 3,139,948 shares of the medical technology company’s stock worth $767,686,000 after acquiring an additional 3,137,089 shares in the last quarter. Cottage Street Advisors LLC grew its stake in shares of Stryker by 20,232.4% in the fourth quarter. Cottage Street Advisors LLC now owns 2,283,735 shares of the medical technology company’s stock worth $462,000 after acquiring an additional 2,272,503 shares during the last quarter. Ontario Teachers Pension Plan Board increased its holdings in shares of Stryker by 87,902.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company’s stock valued at $555,482,000 after acquiring an additional 2,075,371 shares in the last quarter. Finally, FMR LLC raised its position in shares of Stryker by 50.5% in the 1st quarter. FMR LLC now owns 6,012,525 shares of the medical technology company’s stock worth $1,716,396,000 after purchasing an additional 2,017,006 shares during the last quarter. 77.10% of the stock is currently owned by institutional investors.
Stryker Company Profile
Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery.
- Get a free copy of the StockNews.com research report on Stryker (SYK)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.